Buclizine, an oral antihistamine and anti-allergic agent, is known for its potent teratogenic effects in rats and its anti-tumor properties[1].[2].[3].
体内研究
As a teratogen, buclizine dihydrochloride administered between 30 to 200 mg/kg from the tenth to the fifteenth day of gestation demonstrates significant teratogenic effects in rats[3].
体外研究
Buclizine inhibits the growth of MCF-7 cells at concentrations ranging from 0.1 to 100 μM over a period of 72 hours[2].
Additionally, Buclizine affects cell cycle progression, inducing arrest in the G1 phase in a dose-dependent manner between 9.625 and 77 μM over 72 hours[2].
At doses up to 75 μM for the same duration, it also reduces the expression of translationally controlled tumor protein (TCTP) and other cell cycle regulatory proteins in MCF-7 cells, while increasing the expression of the pro-apoptotic protein MCL-1S[2].
搜索
